Login to Your Account

Real-world Nor-switch trial shows biosimilar noninferior to Remicade

By Nuala Moran
Staff Writer

Wednesday, October 19, 2016

LONDON – The first randomized control trial investigating the effect of switching patients from the anti-TNF alpha antibody Remicade to a biosimilar version of infliximab did not show any difference between the two.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription